Regulation & law · 28/12/2020
National Cancer Institute to Grant Exclusive Patent License to Morphiex for Cancer Treatment
The National Cancer Institute is considering granting an exclusive patent license to Morphiex Biotherapeutics to use a CD47 phosphorodiamidate morpholino oligomer for cancer treatment, prevention, and diagnosis.